Published in Drug Week, November 25th, 2005
The study included administering QR-442 to affected mice three times, at days, 1, 3 and 7. The treated mice showed a delayed onset of disease and a significantly lower disease severity than those left untreated.
The Quigley Corporation is a developer and marketer of diversified health products.
This article was prepared by Drug Week editors from staff and other reports. Copyright 2005, Drug Week via...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.